49778 Federal Register / Vol. 76, No. 155 / Thursday, August 11, 2011 / Notices 

for the development of novel diagnostic 

tests and therapeutics. 

Development Stage: Pre-clinical. 

Inventors: Yardena Samuels and 

Xiaomu Wei (NHGRI). 

Publication: Wei X, et al. Exome 

sequencing identifies GRIN2A as 

frequently mutated in melanoma. Nat 

Genet. 2011 May;43(5):442–446. [PMID: 

21499247]. 

Intellectual Property: 

• HHS Reference No. E–013–2011/ 

0—U.S. Provisional Application No. 61/ 

462,471 filed 02 February 2011. 

• Research Tool—Patent protection is 

not being pursued for the TRRAP and 

GRIN2A melanoma metastatic cell lines. 

Related Technologies: 

• HHS Reference No. E–272–2008/ 

0—U.S. Patent Application No. 13/ 

128,125 filed 06 May 2011, European 

and Australian applications filed; 

Mutations of the ERBB4 Gene in 

Melanoma. 

• HHS Reference No. E–229–2010/ 

0—Research Tool; ERBB4 Mutations 

Identified in Human Melanoma 

Metastasis Cell Lines (2690, 2379, 2197, 

2183, 2535, 2645, 1770, 2359, 2238, 

2319, 2190). 

• HHS Reference No. E–232–2010/ 

0—Research Tool; Isocitrate 

Dehydrogenase 1 (IDH1) R132 Mutation 

Human Melanoma Metastasis Cell Line. 

Licensing Contact: Whitney Hastings; 

301–451–7337; hastingw@mail.nih.gov. 

Cells and Nanoparticles With Altered 

Protein Expression Patterns Useful for 

the Modulation of T Cell Activity for 

Immunotherapy 

Description of Technology: NIH 

scientists have developed human cells 

and nanoparticles to enhance 

immunotherapy. Specifically, 

researchers have identified that cells or 

nanoparticles expressing a high 

temperature requirement serine 

peptidase 1 (HtrA1) activator and/or a 

cytokine-induced Src homology 2 

protein (CIS) inhibitor are capable of 

increasing T cell activity. These 

compositions can be used primarily in 

T cell immunotherapy against various 

cancers and infectious diseases where 

enhanced T cell activity is beneficial. 

Conversely, cells or nanoparticles that 

express a HtrA1 inhibitor and/or a CIS 

activator can suppress T cell activity. 

These compositions can be utilized to 

treat various auto- or alloimmune 

diseases and can be used to prevent 

transplant rejections. 

HtrA1 (also known as L56, ARMD7, 

ORF480, and PRSS11) is a serine 

protease that is known to inhibit the 

TGF-beta family proteins. CIS (also 

known as G18, SOCS, CIS–1, and CISH) 

is a member of the suppression of 

cytokine signaling (SOCS) family of 

proteins and inhibit the JAK/STAT 

signaling pathways. CIS acts to inhibit 

HtrA1 and repress cell activation 

targets. Immunotherapy, although an 

effective treatment strategy, sometimes 

fails when cells lose activity. T cells 

adoptively transferred into patients 

where CIS is inhibited and/or HtrA1 is 

activated should maintain their activity 

and lead to more successful adoptive T 

cell transfers. 

Potential Commercial Applications: 

• Immunotherapy for cancer or 

infectious diseases using human cells or 

nanoparticles expressing an HtrA1 

activator and/or a CIS inhibitor 

• Therapeutic for treating 

autoimmune diseases using human cells 

and or nanoparticles expressing an 

HtrA1 inhibitor and/or a CIS activator 

• Agents expressing an HtrA1 

inhibitor and/or a CIS activator to 

prevent organ, tissue, or cell transplant 

rejection and treat alloimmune diseases, 

such as graft-versus-host disease 

• Components of a combination 

therapy to increase or suppress T cell 

activity in a patient 

Competitive Advantages: 

• Some patients do not respond to T 

cell immunotherapy due to lack of cell 

persistence, survival, or activity as well 

as for other poorly understood reasons. 

Modifying HtrA1 and CIS in currently 

existing T cell immunotherapies should 

increase the success rate of these 

therapies by increasing the persistence 

and survival of the infused cells. 

• T cells can become ‘‘exhausted’’ as 

they mature following activation by 

target antigen. Cells with altered 

expression of HtrA1 and/or CIS may be 

able to avoid exhaustion after repeated 

activation. 

Development Stage: 

• Pre-clinical. 

• In vitro data available. 

• In vivo data available (animal). 

Inventors: Douglas C. Palmer and 

Nicholas P. Restifo (NCI). 

Publication: Palmer DC and Restifo 

NP. Suppressors of cytokine signaling 

(SOCS) in T cell differentiation, 

maturation, and function. Trends 

Immunol. 2009 Dec;30(12):592–602. 

[PMID 19879803]. 

Intellectual Property: HHS Reference 

No. E–069–2010/0—U.S. Patent 

Application No. 61/420,825 filed 08 

December 2010. 

Licensing Contact: Samuel E. Bish, 

Ph.D.; 301–435–5282; 

bishse@mail.nih.gov 

Dated: August 5, 2011. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2011–20447 Filed 8–10–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health National 

Institute of Environmental Health 

Sciences; Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

Interagency Breast Cancer and 

Environmental Research Coordinating 

Committee. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: Interagency Breast 

Cancer and Environmental Research 

Coordinating Committee. 

Date: September 26–27, 2011. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: The purpose of the meeting is to 

continue the work of the Committee, to share 

and coordinate information on existing 

research activities, & make recommendations 

to NIH & other Federal agencies on how to 

improve existing research programs related to 

breast cancer & the environment. The agenda 

will be posted on the web: http:// 

www.niehs.nih.gov/about/orgstructure/ 

boards/ibcercc/. 

Place: Nat. Inst. of Environmental Health 

Sciences, Building 101, Rodbell Auditorium, 

111 T. W. Alexander Drive, Research 

Triangle Park, NC 27709. 

Contact Person: Gwen W. Collman, PhD, 

Director, Division of Extramural Research 

and Training (DERT), Nat. Inst. of 

Environmental Health Sciences, National 

Institutes of Health, 615 Davis Dr., KEY615/ 

3112, Research Triangle Park, NC 27709, 

(919) 541–4980, collman@niehs.nih.gov. 

Any member of the public interested in 

presenting oral comments to the Committee 

should submit their remarks in writing at 

least 10 days in advance of the meeting. 

Comments in document format (i.e. WORD, 

Rich Text, PDF) may be submitted via e-mail 

to ibcercc@niehs.nih.gov. You do not need to 

attend the meeting in order to submit 

comments. 

Interested individuals and representatives 

of organizations may submit a letter of intent, 

a brief description of the organization 

represented, and a short description of the 

oral comments you wish to present. Only one 

representative per organization may be 

allowed to present oral comments and if 


srobinson on DSK4SPTVN1PROD with NOTICES
Federal Register / Vol. 76, No. 155 / Thursday, August 11, 2011 / Notices 49779 

accepted by the committee, presentations 

may be limited to five minutes. Both printed 

and electronic copies are requested for the 

record. The statement should include the 

name, address, telephone number and, when 

applicable, the business or professional 

affiliation of the interested person. Oral 

comments will begin at approximately 2:30 

p.m. on Tuesday, September 27, 2011. 

Although time will not be allotted for 

comments on Monday, September 26, 2011, 

members of the public are welcome to attend 

the entire meeting. 

Anyone who wishes to attend the meeting 

and/or submit comments to the committee is 

asked to RSVP via e-mail to 

ibcercc@niehs.nih.gov. Comments are 

delivered to the Contact Person listed on this 

notice. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.115, Biometry and Risk 

Estimation—Health Risks from 

Environmental Exposures; 93.142, NIEHS 

Hazardous Waste Worker Health and Safety 

Training; 93.143, NIEHS Superfund 

Hazardous Substances—Basic Research and 

Education; 93.894, Resources and Manpower 

Development in the Environmental Health 

Sciences; 93.113, Biological Response to 

Environmental Health Hazards; 93.114, 

Applied Toxicological Research and Testing, 

National Institutes of Health, HHS) 

Dated: August 5, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–20438 Filed 8–10–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Library of Medicine; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable materials, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Library of 

Medicine Special Emphasis Panel, R01/R13/ 

R21 Conflicteds. 

Date: September 30, 2011. 

Time: 12 p.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Library of Medicine, 6705 

Rockledge Drive, Suite 301, Bethesda, MD 

20817, (Telephone Conference Call). 

Contact Person: Zoe H. Huang, MD, 

Scientific Review Officer, Extramural 

Programs, National Library of Medicine, NIH, 

6705 Rockledge Drive, Suite 301, Bethesda, 

MD 20892–7968, 301–594–4937, hungz@

mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.879, Medical Library 

Assistance, National Institutes of Health, 

HHS) 

Dated: August 5, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–20439 Filed 8–10–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Nursing Research 

Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

National Advisory Council for Nursing 

Research. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Council for Nursing Research. 

Date: September 20–21, 2011. 

Open: September 20, 2011, 1 p.m. to 5 p.m. 

Agenda: Discussion of Program Policies 

and Issues. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, 6th Floor, C 

Wing, Room 6, Bethesda, MD 20892. 

Closed: September 21, 2011, 9 a.m. to 1 

p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, 6th Floor, C 

Wing, Room 6, Bethesda, MD 20892. 

Contact Person: Yvonne E Bryan, PhD, 

Special Assistant to the Director, National 

Institute of Nursing, National Institutes of 

Health, 31 Center Drive, Room 5B–05, 

Bethesda, MD 20892. 301–594–1580. 

bryany@mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

www.nih.gov/ninr/a_advisory.html, where an 

agenda and any additional information for 

the meeting will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.361, Nursing Research, 

National Institutes of Health, HHS) 

Dated: August 5, 2011. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–20440 Filed 8–10–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Program 

Project: Retina Pathology. 

Date: September 12, 2011. 

Time: 1 to 3:30 p.m. 


srobinson on DSK4SPTVN1PROD with NOTICES